All In Biotech

Drug Trial Radar · NCT07803991

Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes.

A Multicenter, Randomized, Double-blind, Placebo Parallel-Controlled, Phase II Study to Evaluate the Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes

Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Sep 30, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
Sep 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of SYH2069 injection compared with placebo in obese Non-diabetic Participants after 28 weeks of treatment.

Conditions

  • Overweight or Obesity

Interventions

  • SYH2069 InjectionDrug

    0.6ml , 1.2ml , administered subcutaneously (SC),Administer the drug according to the clinical trial protocol

  • SYH2069 Injection PlaceboDrug

    0.6ml , 1.2ml , SC,Administer the drug according to the clinical trial protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative percentage change in body weight from baseline at of treatment at 28 weeks of treatmentTime frame: 28 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.